Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biodonostia (16)

2022

  1. Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors (Scientific Reports, (2018), 8, 1, (12746), 10.1038/s41598-018-30836-5)

    Scientific Reports

  2. Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity

    Cancer Research, Vol. 82, Núm. 7, pp. 1283-1297

2020

  1. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

    Scientific Reports, Vol. 10, Núm. 1

  2. Reply to: Comment to: Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factors

    European Journal of Cancer Prevention

2019

  1. Helicobacter pylori seroprevalence in Spain: Influence of adult and childhood sociodemographic factors

    European Journal of Cancer Prevention, Vol. 28, Núm. 4, pp. 294-303

  2. Liquid biopsy in glioblastoma: Opportunities, applications and challenges

    Cancers, Vol. 11, Núm. 7

2018

  1. Indirect costs associated with glioblastoma: Experience at one hospital

    Neurologia, Vol. 33, Núm. 2, pp. 121-128

  2. PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

    Scientific Reports, Vol. 8, Núm. 1

  3. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

    F1000Research, Vol. 6

2017

  1. High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

    Oncogenesis, Vol. 6, Núm. 12

  2. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study

    Preventive Medicine, Vol. 99, pp. 178-184

2016

  1. Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation

    Neurology, Vol. 87, Núm. 12, pp. 1250-1257

  2. MTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

    Expert Opinion on Therapeutic Targets, Vol. 20, Núm. 4, pp. 393-405

  3. Targeting SOX2 as a therapeutic strategy in glioblastoma

    Frontiers in Oncology

2013

  1. Therapeutic strategies targeting Glioblastoma stem cells

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Núm. 3, pp. 216-227

2010

  1. A Novel PRNP Y218N mutation in gerstmann-sträussler-scheinker disease with neurofibrillary degeneration

    Journal of Neuropathology and Experimental Neurology, Vol. 69, Núm. 8, pp. 789-800